ReviewDrug design, development and therapy2017
Drugs in development for toxoplasmosis: advances, challenges, and current status.
Review in Drug design, development and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 182 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
182 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The effectiveness of congenital toxoplasmosis treatment in minimizing hearing loss: A systematic review.Science progressPooled it
- Highly Selective Thiazole Derivatives as Promising Anti-ACS omega · 2026Article
- Article
- The live attenuatedResearch square · 2026Article
- Structural basis for emetine inhibition of ribosome translocation inbioRxiv : the preprint server for biology · 2026Article
- Article
- Quinolones as anti-Toxoplasma agents: a comprehensive scoping review of in vitro and in vivo efficacy.Parasitology research · 2026Article
- Inhibition of Toxoplasma gondii proliferation by dimethyl itaconate: Evidence from in vitro and in vivo studies.PLoS neglected tropical diseases · 2026Article
- Evolutionary remodeling of ubiquinone biosynthesis in Toxoplasma gondii reveals an essential bi-functional monooxygenase.Nature communications · 2026Article
- Nephrolithiasis associated with sulfadiazine therapy in an infant with congenital toxoplasmosis: a case report.BMC pediatrics · 2026Article
- Bumped Kinase Inhibitor BKI-1708 Interferes in Cytokinesis and Drives Baryzoite Conversion in the Cyst-Forming Apicomplexan ParasitesInternational journal of molecular sciences · 2026Article
- Article
- BKI-1748 confers a high level of protection against ovine congenital toxoplasmosis when administered after IgM seroconversion.Frontiers in cellular and infection microbiology · 2026Article
- Total RNA and MicroRNA Transcriptomic Responses of Human Retinal Müller Glial Cells to Infection withOphthalmology science · 2026Article
- Design, synthesis, and anti-Toxoplasma gondii evaluation of β-carboline derivatives.Parasites & vectors · 2025Article
- Antimicrobial Resistance and the Blood-Brain Barrier: Complex Interactions and Implications for Neurological Health.Molecular neurobiology · 2025Review
- Review of Toxoplasmosis: What We Still Need to Do.Veterinary sciences · 2025Review
- Toxoplasma gondii-induced host's high secretion of 25-hydroxycholesterol for immunoprotection.Parasites & vectors · 2025Article
- In Vivo Safety and Efficacy of Thiosemicarbazones in Experimental Mice Infected withBiomedicines · 2025Article
- Protective Efficacy Induced by Virus-like Particles Expressing Dense Granule Protein 5 ofVaccines · 2025Article
122 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.